E-mail us:
service@prospectnews.com
Or call: 212 374 2800
Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
Add to balance / Manage account
Not logged in
Prospect News home
>
Main news index
>
All issuers starting with A
>
Issuers starting with A, EM only
>
All stories on Allergan plc
>
Stories on Allergan plc, EM only
Search again
Enter part or all of the issuer name:
Market:
All markets
No structured products
Bank loans
Canadian bonds
CLOs
Convertibles
Distressed debt
Emerging markets
High yield
Investment grade
Liability management
Municipals
PIPEs
Preferreds
Private placements
All leveraged markets
Structured products
Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each.
All others are $1.00 each. Headlines in
gray
are not currently covered by your subscription.
Allergan plc
11/12/2019
EMHYPFPV
Market Commentary:
Ford prices split-rated tap; Westpac offers dollar notes; heavy high-grade volume in pipeline
11/8/2019
EMHYPFPV
Market Commentary:
JPMorgan prices $750 million tap; heavy volume expected in week ahead
11/7/2019
EMHYPFPV
Market Commentary:
Patterson-UTI prices downsized notes; FHLBank prints; Hasbro considers deal
11/6/2019
EMHYPFPV
Market Commentary:
Cheniere, Vistra, Equinix, Healthpeak, Ryder, SEK price; AbbVie markets deal
7/13/2016
EMHYMUPFPV
Market Commentary:
Japan Bank, Bank of Montreal, International Finance in primary; Anheuser-Busch flat on day
4/6/2016
EMHYMUPFPV
Market Commentary:
KfW, Banque Federative, Swedish Export bring deals; Pfizer widens; Newell Rubbermaid firms
4/4/2016
EMHYMUPFPV
Market Commentary:
Primary sees $12 billion issuance from Target, BMW, others; Pfizer, AT&T tighten modestly
7/27/2015
BKBWEMIGLM
Teva Pharmaceuticals to obtain up to $27 billion of debt to buy Allergan’s generics business
©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.
